2005
DOI: 10.1016/j.ophtha.2005.06.020
|View full text |Cite
|
Sign up to set email alerts
|

European Glaucoma Prevention Study: Author reply

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
120
1
6

Year Published

2007
2007
2022
2022

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 177 publications
(129 citation statements)
references
References 9 publications
2
120
1
6
Order By: Relevance
“…19 No further RCTs of treatment effectiveness for OAG: other than those included in the systematic review and also separately identified by the search strategy, were identified. One additional RCT 253 was identified where participants had ocular hypertension, but this did not meet the inclusion criteria of this specific review and was excluded.…”
Section: Number and Type Of Studies Includedmentioning
confidence: 99%
“…19 No further RCTs of treatment effectiveness for OAG: other than those included in the systematic review and also separately identified by the search strategy, were identified. One additional RCT 253 was identified where participants had ocular hypertension, but this did not meet the inclusion criteria of this specific review and was excluded.…”
Section: Number and Type Of Studies Includedmentioning
confidence: 99%
“…68 IOP is an imperfect surrogate for the clinical outcomes of glaucoma, as disease can progress despite low IOP or remain stable despite IOP levels considered high. [69][70][71] The use of visual fields as an end point is potentially limited by the need for large samples, long follow-up, variability of results, and inconsistency in criteria for defining progression. 72 The absence of regulatory support for other glaucoma end points has been identified as a weakness in exploring candidate agents for neuroprotective therapy and alternative surrogate end points have been sought.…”
Section: Summary and Future Directionsmentioning
confidence: 99%
“…In this study, treatment reduced the IOP by 15-22% throughout the 5 years of the trial, and interestingly an IOP lowering effect of between 9 and 19% reduction in IOP was observed in the placebo group. 17 Combining these data and data from eight smaller trials a Cochrane systematic review and meta-analysis by Vass and colleagues evaluating different topical medications against placebo or untreated controls showed about a 40% reduction in the incidence of glaucomatous visual field defects with treatment at five years (odds ratio 0.62 (95% confidence interval 0.5 to 0.8) for people with ocular hypertension. 18 In the UK there is great variability in clinical practice regarding standards of care (follow-up and treatment) of ocular hypertension.…”
Section: Resultsmentioning
confidence: 99%